Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Drug Reps Soften Their Sales Pitches
WSJ Online
Tuesday, January 10, 2012 - 9:15am
tags:
drug reps
Super Painkiller Needs Extra Scrutiny From FDA, NY Senator Says
Bloomberg
Tuesday, January 10, 2012 - 9:06am
tags:
painkillers, FDA, Zogenix
Next Amgen CEO sees expansion to new markets, higher sales from newer products, share buybacks
Yahoo/AP
Tuesday, January 10, 2012 - 9:05am
tags:
Amgen, Pharma CEOs, Robert Bradway
The New Amylin - More Risk, More Potential
Seeking Alpha
Tuesday, January 10, 2012 - 9:05am
tags:
Amylin, Bydureon, diabetes
A White Hot Hep C Market: What The Wags Say
Pharmalot
Monday, January 9, 2012 - 1:24pm
tags:
hepatitis C, Inhibitex, Bristol-Myers Squibb, Gilead, Pharmasset, M&A
Allergan to plow $350M into bigger Botox capacity
Fierce Pharma
Monday, January 9, 2012 - 12:01pm
tags:
Botox, Allergan
Inside Wall Street: Celgene is an attractive biotech
MSN Money
Monday, January 9, 2012 - 11:59am
tags:
Celgene
Alexion Shares Hit 52-Week High
TheStreet.com
Monday, January 9, 2012 - 11:41am
tags:
Alexion
JPM kicks off with fevered focus on the next big biotech deal
Fierce Biotech
Monday, January 9, 2012 - 10:42am
tags:
JPMorgan, biotech, M&A, Inhibitex, Bristol-Myers Squibb
Biotech Investors Buoyed By Signs Of Speedier Drug Launches
Seeking Alpha
Monday, January 9, 2012 - 10:40am
tags:
drug launches, Dendreon, Incyte, Human Genome Sciences, Regeneron, Seattle Genetics, Vertex
2 ETFs To Play A Surge In Biotech/Pharma M&A
Seeking Alpha
Monday, January 9, 2012 - 10:39am
tags:
Abbott Laboratories, Amgen, Biogen Idec, Gilead, Celgene, Bristol-Myers Squibb, JNJ, Eli Lilly, Merck, Pfizer, ETFs
Vivus obesity drug may get broader label
Reuters
Monday, January 9, 2012 - 10:30am
tags:
obesity, Vivus, Qnexa
Idenix reports positive interim data for HCV Nucleotide Inhibitor, IDX184
Yahoo/Fly on the Wall
Monday, January 9, 2012 - 10:30am
tags:
Idenix, hepatitis C, nucleotide inhibitor, IDX184
Dendreon Rally Justified, But Outstanding Issues May Limit Upside
Seeking Alpha
Monday, January 9, 2012 - 10:29am
tags:
Dendreon, Provenge
There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake
InPharm
Monday, January 9, 2012 - 10:14am
tags:
guidance, AstraZeneca
Bristol’s Buy of Inhibitex for Hepatitis Drug Won’t Be Last
Bloomberg
Monday, January 9, 2012 - 10:12am
tags:
Bristol-Myers Squibb, M&A, Inhibitex, hepatitis C
Five Myths You’ll Hear This Week at the JP Morgan Healthcare Conference
Xconomy
Monday, January 9, 2012 - 10:10am
tags:
JPMorgan, IPOs, Amgen, FDA, innovation
Novartis Recalls OTC Meds Made At Troubled Plant
Pharmalot
Monday, January 9, 2012 - 10:03am
tags:
Novartis, recalls, OTC
Optimer provides update on DIFICID tablets launch
The Fly on the Wall
Monday, January 9, 2012 - 10:01am
tags:
Optimer, Dificid
Shares of hepatitis C drug developers rise on Bristol-Myers' $2.5B deal for Inhibitex
Yahoo/AP
Monday, January 9, 2012 - 9:57am
tags:
hepatitis C, Bristol-Myers Squibb, M&A, Inhibitex, Gilead, Pharmasset

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.